Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma
Purpose: The use of erythropoietin in head and neck squamous cell carcinoma (HNSCC) has been associated with poor survival. This study examines the protein and mRNA expression of erythropoietin and erythropoietin receptor in HNSCC and their relation to hypoxia, hemoglobin (Hb), and clinical outcome....
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2005-11, Vol.11 (21), p.7614-7620 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: The use of erythropoietin in head and neck squamous cell carcinoma (HNSCC) has been associated with poor survival. This study
examines the protein and mRNA expression of erythropoietin and erythropoietin receptor in HNSCC and their relation to hypoxia,
hemoglobin (Hb), and clinical outcome.
Experimental Design: The immunohistochemical expression of erythropoietin and erythropoietin receptor was assessed in 151 cases of HNSCC. Expression
was compared with the hypoxia-dependent proteins hypoxia-inducible factor-1α (HIF-1α) and carbonic anhydrase-9 (CA-9) and
correlated with clinical outcome. The mRNA expression of erythropoietin and erythropoietin receptor was measured in paired
samples of HNSCC.
Results: Erythropoietin and erythropoietin receptor were expressed in 95% and 99% of tumors, respectively. Using a weighed expression
score, there was a positive correlation between erythropoietin and erythropoietin receptor expression ( r = 0.18, P = 0.03). HIF-1α ( r = 0.38, P < 0.01) and CA-9 ( r = 0.26, P = 0.002) correlated with erythropoietin expression, but there was no correlation with erythropoietin receptor. No correlation
was found between Hb and erythropoietin ( r = 0.07, P = 0.36) or erythropoietin receptor ( r = −0.02, P = 0.8), and no survival difference between high and low erythropoietin or erythropoietin receptor expression ( P = 0.59 and P = 0.98, respectively). The mRNA expression of erythropoietin ( P = 0.03) but not erythropoietin receptor ( P = 0.62) was significantly increased in 11 paired samples of HNSCC.
Conclusion: In vivo , the HIF pathway regulates erythropoietin at the mRNA level but not erythropoietin receptor expression in HNSCC. Anemia does
not seem to influence the hypoxic microenvironment of tumors sufficiently to alter the expression of erythropoietin. The effects
of exogenous erythropoietin may be acting via receptors expressed on tumor cells in vivo , or on vascular cells, which also express the pathway. |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-05-1097 |